Our client in China is looking to spin off its assets offshore and restructure corporate structure for both company development and exit considerations.
Our client in the US is looking for partners in China and Japan to further develop and commercialize its ground breaking technology in ophthalmology in those significant markets.
Our client is a Nasdaq listed biotech company looking to acquire another public listed company for synergistic pipeline assets as well as risk mitigation.
Our client is looking to out license its Phase II /III clinical stage assets. They already have a term sheet from a major pharmaceutical company but are looking to run a broader process to maximize asset value.
Our clients in the US, EU, Asia are earlier stage biotech/medtech companies looking to raise venture/growth capital from Series A to crossover pre-IPO rounds.
Our client in China is looking for commercial partners for its proprietary veterinary biologics in the US and EU markets.
Laurel Hollow Capital
Copyright © 2024 Laurel Hollow Capital - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.